TCET Final Notice Leaves Much To Be Desired, Eyes Turn To Congress

The long-awaited TCET final notice doesn’t address major concerns, medtech industry advocates say.

• Source: Shutterstock

The Transitional Coverage for Emerging Technology (TCET) final notice from the Centers for Medicare and Medicaid Services (CMS) doesn’t address the concerns from its draft, leaving the medtech industry to put their hopes behind Congress’s Ensuring Patient Access to Critical Breakthrough Products Act of 2023 (H.R. 1691).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Policy & Regulation

More from Medtech Insight

Execs On The Move: 14-18 April 2025

 
• By 

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

AAOS 2025 Orthopedic Roundup: J&J Velys UKA, Stryker Mako 4, Materialise, Canary Medical

 
• By 

At AAOS, orthopedics players showcased their latest robotic-assisted platforms, power tools, 3D printed technologies and software offerings. This article brings you highlights from interviews Medtech Insight conducted on site with representatives from J&J, Stryker, Materialise and Canary Medical.

South Korea Adds Digital Health Rules To Already Complicated Regulatory Landscape

 
• By 

A New South Korean law, the Digital Medical Products Act, enhances regulation for digital health products. Medical devices in the country are categorized both by risk and by similarity to already authorized devices. The approval process may stretch to 515 days for new manufacturers.